Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 4Phase 2/3 2Phase 1/2 1

Status

Completed 33Terminated 12Recruiting 5Active not recruiting 5Withdrawn 4Unknown 3

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Lymphoma 1Leukemia, Plasma Cell 1Desmoid Tumors 1Breast Neoplasms 1

Interventions

Cyclophosphamide 35Cisplatin 24fludarabine 23Radiotherapy 23Paclitaxel 21Carboplatin 20pembrolizumab 18Nivolumab 18Magnetic Resonance Spectroscopy 18Specimen Handling 17fludarabine phosphate 15Gemcitabine 15Biopsy 15Cytarabine 14Radiation 11Filgrastim 11Doxorubicin 11Docetaxel 11Dexamethasone 11Radiosurgery 10Granulocyte Colony-Stimulating Factor 10Etoposide 10Melphalan 9Ipilimumab 9venetoclax 8Rituximab 8Calcium Dobesilate 8trametinib 7ibrutinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × liposomal doxorubicin × Clear all
NCT02557854 2019-03-19

HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors

University of Texas Southwestern Medical Center

Phase 1 Withdrawn
CNSSarcoma

Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoid Tumors

NCT03591744 2018-12-19

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

City of Hope Medical Center

Phase 1 Withdrawn
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT01490047 2015-06-16

Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas

Ludwig Institute for Cancer Research

Phase 1 Withdrawn
Lymphoid

Lymphoma

NCT01333423 2012-06-26

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡